Can scans predict which liver cancer patients need extra local therapy?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years on the index date. * Receipt of at least one dose each of atezolizumab and bevacizumab as part of the same first-line combination regimen, with an interval of ≤28 days between the first administrations of the two drugs. * At least one intrahepatic lesion amenable to a protocol-specified LRT on the index date, with no absolute contraindication to Atezo+Bev or to all feasible LRTs. * A clinical, radiologic, or pathologic diagnosis of uHCC on or before the index date; baseline EHS is permitted. * Survival status or the date last known alive after the index date can be ascertained. * No systemic therapy for HCC before the regimen initiation date. * No LRT within 60 days before the index date or between baseline imaging and the index date; earlier prior LRTs are permitted provided that an untreated, measurable intrahepatic lesion remains. * A technically adequate baseline contrast-enhanced CT/MRI examination and at least one untreated intrahepatic lesion that can be delineated and evaluated. * Baseline ECOG performance status of 0-2. Exclusion Criteria: * Another primary malignancy requiring active systemic treatment on the index date, except for a malignancy that has been cured and has a low risk of recurrence. * Participation on the index date in an interventional study that could affect treatment allocation or outcome assessment. * Suitability for immediate curative resection or liver transplantation following multidisciplinary assessment. * An absolute contraindication to Atezo+Bev or to all feasible LRTs. * Active autoimmune disease or immunodeficiency requiring systemic immunosuppression or constituting a contraindication to atezolizumab. Inadequately controlled high-risk esophageal/gastric varices, recent variceal bleeding, an uncorrected bleeding tendency, or clinically significant coagulopathy. * Inability to determine the index date, primary treatment strategy, OS outcome/censoring date, or absence of a technically adequate baseline contrast-enhanced CT/MRI examination.